PHARMA MAR, S.A. «12345...» Page 1 out of 10 from 01/07/1988 to 22/03/2018 The price-sensitive information presented in other languages is a literal translation of the price-sensitive information stated in Spanish 21/03/2018 19:24 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks In relation to the Significant Fact n. 260272 the EMA has advanced to Pharma Mar that the CHMP confirms its negative Opinion issued in December 2017 in relation to Aplidin in the multiple myeloma indication. Register number: 263165 Related with 270099 of 02/10/2018 (08:14) 28/02/2018 18:20 PHARMA MAR, S.A. Board of directors remuneration annual statement La Sociedad remite el Informe Anual sobre remuneraciones de los consejeros del Ejercicio 2017 Register number: 262365 28/02/2018 17:55 PHARMA MAR, S.A. Corporate governance annual report La sociedad remite el Informe Anual de Gobierno Corporativo del ejercicio 2017 Register number: 262348 28/02/2018 17:52 PHARMA MAR, S.A. Information on P&L The Company sends release regarding year 2017 results. Register number: 262346 28/02/2018 17:41 PHARMA MAR, S.A. Interim financial information La sociedad remite información sobre los resultados del segundo semestre de 2017 Register number: 262335 14/02/2018 08:15 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks Pharma Mar licenses fully synthetic marine derived payloads to Seattle Genetics for use in drug conjugates. Register number: 261551 18/01/2018 19:00 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks CORAIL Phase III with Zepsire in resistant ovarian cancer has not met its primary endpoint. Register number: 260786 11/01/2018 17:58 PHARMA MAR, S.A. Liquidity contracts and specialists The Company reports details of the operations of the Liquidity Agreement between 11/10/2017 and 10/01/2018 Register number: 260607 09/01/2018 14:13 PHARMA MAR, S.A. Strategic plans, profit forecasts and presentations New corporate presentation (English version) which will be available in the Company´s web site. Register number: 260513 03/01/2018 09:24 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks In relation to the Significant Fact n. 259611, PharmaMar has requested from the European Medicines Agency the re-examination of the negative Opinion issued by the CHMP for Aplidin® for the indication of relapsed and refractory multiple myeloma. Register number: 260272 Page 1 out of 10 «12345...»